Melanoma Nursing Initiative Resources Customized for the Australian Audience

Stage II Melanoma Treatment Videos

In the following videos, Professor Grant McArthur, Executive Director of the Victorian Comprehensive Cancer Center discusses the use of treatments in patients with melanoma. The videos address whether to treat, the risks versus benefits of treatment and the differences between the stages IIA, B and C. The content is customised to the Australian region. This content was recorded in March 2024.

What is stage II Melanoma?

What are the side effects of treatment?

How is stage IIA melanoma treated?

Is stage II melanoma at high risk for coming back?

How do you weigh the benefits and risks of melanoma treatment vs no treatment?

How is stage IIB and C melanoma treated?

Sequencing of Therapies in Stage IV Melanoma

In this video series, Dr. Miles Andrews, a Medical Oncologist and Head of Immuno-oncology at The Alfred, discusses sequencing strategies for Stage IV melanoma. The videos address strategies for neoadjuvant and adjuvant therapy, first-line and subsequent lines of therapy, single-agent and combination immunotherapy, BRAF-targeted therapy, the management of brain metastases, clinical trials, and management of refractory disease. The videos were recorded on February 6, 2024.

When should neoadjuvant or adjuvant therapy be considered in stage IV disease?

Which immunotherapy should be used for front-line BRAF wild-type patients?

Which combination should be used after progression post PD-1 therapy?

What is the role for BRAF-targeted therapy?

How should strategies be personalised for management of brain metastases?

Strategies for refractory disease

When should a clinical trial be considered?

New! Stage IV Decision-Support Tool

Welcome to this guide, Stage IV Melanoma Treatment Options: Making the Decision That’s Right for You. You can use this guide to discuss therapeutic options for managing Stage IV melanoma with your patients.

The document addresses

  • Stage IV melanoma clinical picture, biomarkers and pathology, and disease and patient factors involved in decision making
  • Efficacy, safety, and administration of targeted therapies, immune checkpoint inhibitors, and other therapies used for stage IV melanoma
  • Management of brain metastases, including radiation therapy
  • Clinical trials, including an overview of emerging therapies being studied
  • Diagnosis (including biopsy techniques) as well as an overview of imaging

Developed in collaboration with the Melanoma Skin Cancer Advocacy Network (MSCAN).

New videos from oncology experts! Immunotherapy Combination Therapy: Current and Emerging Approaches

In this video series, Lavinia Spain, MBBS(Hons), BMedSci FRACP, from Peter MacCallum Cancer Center discusses current and emerging perspectives on the use of combination immunotherapy in oncology. These videos, developed for the Australian audience, discuss the rationale for combination therapy, the data supporting the combination approaches, patient selection for combination immunotherapy versus other options, managing the more complex side effects associated with this approach, as well as new strategies of combined immunotherapy. We hope that this content will be useful for you to select and manage the best immunotherapy regimens for your cancer patients.

Rationale for Combined Immunotherapy

What are the data to support the use of combination Immunotherapy?

Patient Selection for Combination Immunotherapy

Managing the Complex Adverse Effect Profile of Combination Immunotherapy

Emerging Strategies for Combination Immunotherapy

Stage III Decision- Support Materials

Updated Stage III Decision Support Tool

The Decision-Support Tool has been updated with information you need to know about outcomes for Stage III melanoma, long-term data for adjuvant therapies, and additional resources, including content specific for caregivers.

Developed in collaboration with the Melanoma & Skin Cancer Advocacy Network.

New Stage III Companion Piece

Want to learn how to use the Stage III Decision-Support Tool? Peruse frequently asked questions about Stage III melanoma and learn how to use the support tool to guide your decision making.

Developed in collaboration with Melanoma & Skin Cancer Advocacy Network.

New! BRAF Q&A Compendium

BRAF in Melanoma: Answering Questions, Addressing Misconceptions

In the resources provided below, the AIM at Melanoma Foundation provides answers to questions and addresses misconceptions raised by patients regarding BRAF in melanoma. The patient-directed resources address what BRAF is, the role of BRAF in melanoma, what BRAF mutational status means, testing for BRAF, and the implications of the test results for treatment planning. The answers are provided by Lisa Kottschade, APRN, MSN, CNP, Associate Professor of Oncology at the Mayo Clinic in Rochester, Minnesota, and an expert faculty member of the Melanoma Nursing Initiative.

We thank Novartis Pharmaceuticals for an unrestricted educational grant in support of this important educational initiative. We also thank Tamara Dawson, of the Melanoma & Skin Cancer Advocacy Network, for her review and customization of these materials for the Australian audience.

Print out this pamphlet, which provides Ms. Kottschade’s commentary for specific questions/statements about BRAF.

BRAF Q&A Videos

Click on the videos below to watch Ms. Kottschade’s commentary about BRAF. Below the videos, we have also listed some resources patients might find helpful as they navigate BRAF testing and management of their melanoma.


“What Is BRAF?”

“So BRAF is inherited. If my parents have the mutation, I will inherit it.”

“If I have a BRAF mutation, does that mean I need to get screened for other cancers?”


“I am young, so it makes sense that my tumour would have a BRAF mutation.”

“I am BRAF positive. That’s bad. It means my tumour will come back.”

“I am BRAF negative. That means I am going to be OK.”

“You need to know your BRAF status, because it will tell you how you developed your melanoma and what you need to avoid so you don’t develop another one.”


“Who should be tested for BRAF?”

“How is the BRAF test performed?”

“How long does the test take to perform?”

“How long does the test take to perform??”

“Is the BRAF test reimbursed?”


“If I am BRAF positive, it means I’m being treated with regular chemotherapy.”

“If I find out that I’m BRAF positive, then I’ll have to take the “BRAF drug” before they allow me to take the really good medicine, immunotherapy.”

“If I am BRAF negative, I won’t be able to get an effective therapy.”